Around three-fourths of the layoffs are slated for November, with the rest expected in February. Theravance says the reduced headcount will save the company approximately $165 million in annualized operating expenses next year, and help it to sustain positive cash flow by the second half of 2022.
https://www.biopharmadive.com/news/theravance-layoffs-employees-restructuring/606604/